CALCA and migraine disorder: By April 2022, three anti-CGRP mAbs were reimbursed in Spain for preventive migraine treatment for adults with ≥ 8 migraine days a month and ≥ 3 prior treatment failures – necessarily including botulinum toxin type A [BoNT/A] for CM [33].